Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Pharma
GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
With checkpoint inhibitors like Keytruda and Opdivo now sporting subQ formulations, GSK wants to ensure its own PD-1 drug doesn’t miss out on the action.
Fraiser Kansteiner
Jan 20, 2026 2:26pm
FDA limits Keytruda, Opdivo uses in stomach cancer
Jun 9, 2025 10:50am
ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop
Jun 3, 2025 8:00am
Sun Pharma buys Checkpoint Therapeutics for up to $416M
Mar 10, 2025 10:23am
Leo bags Loqtorzi rights, putting marketing muscle behind launch
Jan 21, 2025 11:15am
GSK trial result mirrors Merck's problem in ovarian cancer
Dec 20, 2024 10:46am
